Metabolic response to surgery in the cancer patient: consequences of aggressive multimodality therapy.
The metabolic response to uncomplicated surgery in the patient undergoing primary therapy for malignancy is no different than the response to surgery of similar magnitude for benign disease. Hemodynamic, nutritional-endocrine, and convalescent changes are similar. However, with current aggressive approaches to the management of cancer, the patient often comes to surgery with evidence of major debilitating side effects from his progressive malignancy or from aggressive multimodality therapy. The surgeon must be aware of the consequences of the use of combination therapies on the expected metabolic response to surgery. Awareness of such problems such as the nutritional deficit will allow preventive methods to supercede metabolic salvage procedures.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D005260:Female; D006439:Hemodynamics; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D008297:Male; D009369:Neoplasms / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D009748:Nutrition Disorders / Q000209:etiology*; D011183:Postoperative Complications; D011832:Radiation Injuries; D051381:Rats; D014945:Wound Healing
D000970:Antineoplastic Agents